Figure 2.

Forest plot of direct estimates for: A – infliximab (5 mg) vs. placebo and adalimumab (160/80 mg) vs. placebo, and indirect comparison between the treatments in the case of clinical remission after 6–8 weeks of drug administration; B – infliximab (5 mg) vs. placebo and adalimumab (160/80 mg) vs. placebo, and indirect comparison between treatments in the case of clinical remission after 52–54 weeks of drug administration; C – infliximab (5 mg) vs. placebo and golimumab (200/100 mg) vs. placebo, and indirect comparison between treatments in the case of clinical remission after 6–8 weeks of drug administration; D – infliximab (5 mg) vs. placebo and golimumab (100 mg) vs. placebo, and indirect comparison between treatments in the case of clinical remission after 52–54 weeks of drug administration